Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Helix Biopharma Corp T.HBP

Alternate Symbol(s):  HBPCF

Healthcare Biotechnology
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant... see more

Recent & Breaking News (TSX:HBP)

Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan

TheNewsWire 8 days ago

Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services

TheNewsWire April 3, 2025

Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting

TheNewsWire March 26, 2025

Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025

TheNewsWire March 18, 2025

Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain

TheNewsWire March 11, 2025

Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts

TheNewsWire March 6, 2025

Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

TheNewsWire March 3, 2025

Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

TheNewsWire February 24, 2025

Helix Biopharma Corp. Announces Closing of Private Placement of Common Shares

TheNewsWire January 9, 2025

Helix BioPharma Corp. Appoints James B. Murphy as Chief Financial Officer

TheNewsWire December 11, 2024

Helix BioPharma Amends Acquisition Agreements to Finalise Share Consideration Ahead of Potential Financing

TheNewsWire December 6, 2024

Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Gemcitabine Chemotherapy Compound

TheNewsWire December 2, 2024

Helix Biopharma Corp. Enters into Asset Purchase Agreement to Acquire Oral Immune Checkpoint Inhibitor and Expand Immune-Oncology Portfolio

TheNewsWire November 29, 2024

Helix Biopharma Corp. Announces Issuance of U.S. Patent

TheNewsWire November 21, 2024

Helix BioPharma Corp. Enters into Non-Binding Letter of Intent to Acquire Laevoroc Group's Oncology Assets

TheNewsWire November 13, 2024

Helix BioPharma Corp. Attends World ADC San Diego

TheNewsWire November 11, 2024

Helix Biopharma Corp. Announces CFO and Corporate Secretary Resignation

TheNewsWire November 8, 2024

Canadian Investment Regulatory Organization Trade Resumption - HBP

Canada NewsWire April 1, 2024

Canadian Investment Regulatory Organization Trading Halt - HBP

Canada NewsWire March 28, 2024

Helix BioPharma Corp. Reports Voting Results

TheNewsWire January 18, 2024